reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
Reconciliation_NOMZ
to_PIN
Accounting_GER
Principles_NN
The_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
which_WDT [WHSUB]
differs_VPRT
in_PIN
certain_JJ
respects_NN
from_PIN
US_FPP1
GAAP_NN
._.
The_DT
tables_NN
below_PLACE
summarise_NN
the_DT
material_NN
adjustments_NOMZ
to_PIN
the_DT
loss_NN
profit_NN
for_PIN
the_DT
year_NN
and_PHC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
Notes_NN
000_CD
000_CD
Loss_NN
profit_NN
under_IN
UK_NN
GAAP_NN
43,223_CD
1,109_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Purchase_NN
accounting_GER
and_PHC
goodwill_NN
Amortisation_NOMZ
of_PIN
goodwill_NN
and_CC
other_JJ
intangibles_NN
1a_NN
,_,
c_NN
,_,
d_SYM
3,664_CD
3,399_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
1b_VPRT
823_CD
518_CD
Investments_NOMZ
1c_CD
1,893_CD
Write-off_PIN
of_PIN
acquired_VBN
in-process_JJ
R&D_NN
1e_CD
4,646_CD
Deferred_JJ
taxes_NN
1c_VPRT
139_CD
401_CD
Share-based_JJ
compensation_NOMZ
4_CD
751_CD
181_CD
Revenue_NN
recognition_NOMZ
5_CD
13,386_CD
26,987_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
Revenue_NN
recognition_NOMZ
6_CD
6,126_CD
14,219_CD
Interest_NN
expense_NN
6_CD
9,609_CD
5,850_CD
Royalty_NN
payments_NOMZ
6_CD
3,144_CD
664_CD
Financial_NN
instruments_NOMZ
8_CD
146_CD
531_CD
Net_JJ
loss_NN
under_IN
US_FPP1
GAAP_NN
37,084_CD
45,261_CD
Net_JJ
loss_NN
per_PIN
Ordinary_NN
Share_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
6.1_CD
p_NN
7.8_CD
p_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
Notes_NN
000_CD
000_CD
Shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
86,265_CD
124,270_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Purchase_NN
accounting_GER
and_PHC
goodwill_NN
Goodwill_NN
1a_CD
,_,
c_NN
,_,
d_SYM
85,226_CD
83,719_CD
Other_JJ
intangible_JJ
fixed_JJ
assets_NN
1a_NN
,_,
c_NN
4,378_CD
4,344_CD
Tangible_JJ
fixed_JJ
assets_NN
1b_VPRT
7,946_CD
7,930_CD
Investments_NOMZ
1c_CD
1,893_CD
Deferred_JJ
taxes_NN
1c_VPRT
1,578_CD
1,439_CD
Contingent_JJ
consideration_NOMZ
charged_VBN [WZPAST]
to_PIN
goodwill_NN
reserve_NN
1e_CD
22,620_CD
22,620_CD
Shares_NN
issued_VBN
relating_VBG
to_PIN
contingent_JJ
consideration_NOMZ
3_CD
11,310_CD
11,310_CD
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
,_,
deferred_VBN
shares_NN
and_PHC
shares_NN
issued_VBN
2_CD
11,310_CD
11,310_CD
Share-based_JJ
compensation_NOMZ
4_CD
1,056_CD
305_CD
Employee_NN
benefit_NN
trust_NN
7_CD
1,800_CD
1,859_CD
Deferred_JJ
revenue_NN
5_CD
10,887_CD
23,179_CD
Funding_GER
liabilities_NOMZ
6_CD
51,224_CD
37,698_CD
Financial_NN
instruments_NOMZ
8_CD
354_CD
500_CD
Shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
101,732_CD
138,530_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
86_CD
87_CD
reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
Summary_NN
of_PIN
Material_NN
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
The_NN
adjustments_NOMZ
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
relating_VBG [WZPRES]
to_PIN
the_DT
RTP_NN
acquisition_NOMZ
are_VPRT
mainly_RB
differences_NN
in_PIN
i_FPP1
the_DT
valuation_NOMZ
1_CD
Business_NOMZ
combinations_NOMZ
Under_IN
both_DT
UK_NN
and_PHC
US_FPP1
GAAP_NN
of_PIN
contingent_JJ
purchase_NN
price_NN
consideration_NOMZ
and_CC
ii_VB
the_DT
methods_NN
the_DT
acquisitions_NOMZ
of_PIN
Jago_NN
Holdings_GER
AG_NN
,_,
SkyePharma_NN
Production_NOMZ
of_PIN
purchase_NN
price_NN
allocation_NOMZ
._.
SAS_NN
formerly_TIME
Laboratories_NN
Novalis_NN
Production_NOMZ
SAS_NN
,_,
SkyePharma_NN
Inc._NN
formerly_TIME
DepoTech_NN
Corporation_NOMZ
,_,
SkyePharma_NN
Canada_NN
Inc._NN
._.
Contingent_JJ
consideration_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
contingent_JJ
consideration_NOMZ
formerly_TIME
RTP_NN
Pharma_NN
Inc._NN
and_PHC
SkyePharma_NN
AB_NN
are_VPRT [PASS]
accounted_VBN
had_VBD [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
cost_NN
._.
The_DT
deferred_VBN
for_PIN
as_IN
acquisitions_NOMZ
purchases_NN
._.
Both_DT
UK_NN
and_PHC
US_FPP1
GAAP_NN
require_VPRT [SUAV] [THATD]
the_DT
consideration_NOMZ
became_VBD
payable_JJ
on_PIN
30_CD
June_NN
2003_CD
and_CC
the_DT
fair_JJ
value_NN
purchase_NN
consideration_NOMZ
to_TO
be_VB [PASS]
allocated_VBN
to_PIN
the_DT
net_JJ
assets_NN
acquired_VBN [WZPAST]
of_PIN
3,690,211_CD
additional_JJ
SkyePharma_NN
shares_NN
were_VBD [PASS]
recorded_VBN
as_RB
at_PIN
their_TPP3
fair_JJ
value_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
,_,
with_PIN
the_DT
difference_NN
goodwill_NN
during_PIN
the_DT
year_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Company_NN
applied_VBD
between_PIN
the_DT
consideration_NOMZ
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
assets_NN
EITF_NN
97-15_CD
,_,
Accounting_GER
for_PIN
Contingency_NN
Arrangements_NOMZ
Based_VBD
on_PIN
acquired_VBN
treated_VBN
as_IN
goodwill_NN
._.
In_PIN
the_DT
allocation_NOMZ
of_PIN
consideration_NOMZ
,_,
Security_NOMZ
Prices_NN
in_PIN
a_DT
Purchase_NN
Business_NOMZ
Combination_NOMZ
to_TO
estimate_VB [PRIV]
and_CC
the_DT
treatment_NOMZ
of_PIN
contingent_JJ
consideration_NOMZ
,_,
certain_JJ
differences_NN
the_DT
contingent_JJ
consideration_NOMZ
as_IN
of_PIN
the_DT
acquisition_NOMZ
date_NN
._.
Under_IN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
arise_VB
as_RB
set_VBN
out_PIN
below_PLACE
._.
EITF_NN
97-15_CD
a_DT
contingency_NN
arrangement_NOMZ
that_TSUB
does_VPRT
not_XX0
result_VB
in_PIN
a_DT
guarantee_NN
of_PIN
the_DT
minimum_JJ
value_NN
of_PIN
the_DT
total_JJ
consideration_NOMZ
should_NEMD
a_DT
Goodwill_NN
and_CC
other_JJ
intangible_JJ
fixed_JJ
assets_NN
Prior_RB
to_PIN
the_DT
be_VB [PASS]
recorded_VBN
at_PIN
an_DT
amount_NN
equal_JJ
to_PIN
the_DT
maximum_JJ
number_NN
of_PIN
shares_NN
introduction_NOMZ
of_PIN
FRS10_NN
,_,
as_IN
permissible_JJ
under_IN
UK_NN
GAAP_NN
,_,
no_DT
that_DEMP
could_POMD
be_VB [PASS]
issued_VBN
multiplied_VBN
by_PIN
the_DT
fair_JJ
value_NN
per_PIN
share_NN
at_PIN
the_DT
intangible_JJ
assets_NN
had_VBD [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_CONJ
a_NULL
result_NULL
of_PIN
purchase_NN
date_NN
of_PIN
the_DT
acquisition_NOMZ
._.
However_CONJ
,_,
the_DT
recorded_VBN
amount_NN
may_POMD
not_XX0
accounting_VBG
as_IN
the_DT
intangible_JJ
assets_NN
were_VBD [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
an_DT
exceed_VB
the_DT
target_NN
value_NN
of_PIN
the_DT
consideration_NOMZ
issued_VBN [WZPAST]
at_PIN
the_DT
date_NN
integral_JJ
part_NN
of_PIN
the_DT
business_NOMZ
acquired_VBD
and_PHC
were_VBD
,_,
therefore_CONJ
,_,
included_VBD
of_PIN
acquisition_NOMZ
i._FW
e._FW
the_DT
lowest_JJ
total_JJ
value_NN
at_PIN
which_WDT [PIRE]
additional_JJ
within_PIN
goodwill_NN
and_CC
eliminated_VBN
against_PIN
shareholders_NN
funds_NN
._.
Where_RB
consideration_NOMZ
would_PRMD
not_XX0
be_VB [PASS]
required_VBN [SUAV]
to_TO
be_VB [PASS]
issued_VBN
._.
The_DT
subsequent_JJ
the_DT
aggregate_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
exceeded_VBD
issuance_NN
of_PIN
additional_JJ
consideration_NOMZ
resulting_VBG [WZPRES]
from_PIN
either_DT
of_PIN
these_DEMO
the_DT
cost_NN
of_PIN
the_DT
acquired_VBN
net_JJ
assets_NN
resulting_VBG [WZPRES]
in_PIN
negative_JJ
goodwill_NN
,_,
security_NOMZ
price_NN
contingencies_NN
does_VPRT
not_XX0
change_VB
the_DT
recorded_VBN
cost_NN
such_JJ
excess_NN
was_VBD [PASS]
credited_VBN
directly_RB
to_PIN
reserves_NN
._.
The_DT
Group_NN
adopted_VBD
of_PIN
the_DT
acquisition_NOMZ
._.
The_DT
application_NOMZ
of_PIN
the_DT
provisions_NN
of_PIN
EITF_NN
97-15_CD
transitional_JJ
provisions_NN
under_IN
FRS10_NN
and_CC
accordingly_RB
did_VBD
not_XX0
reinstate_VB
has_VPRT [PEAS]
resulted_VBN
in_PIN
a_DT
2.6_CD
million_CD
increase_NN
in_PIN
the_DT
purchase_NN
consideration_NOMZ
._.
goodwill_NN
previously_TIME
eliminated_VBN
against_PIN
reserves_NN
as_IN
an_DT
intangible_JJ
asset_NN
._.
Purchase_NN
price_NN
allocation_NOMZ
Under_IN
US_FPP1
GAAP_NN
an_DT
intangible_JJ
asset_NN
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
an_DT
allocation_NOMZ
of_PIN
the_DT
purchase_NN
consideration_NOMZ
shall_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
apart_RB
from_PIN
goodwill_NN
if_COND
it_PIT
arises_VPRT
to_PIN
identifiable_JJ
intangible_JJ
assets_NN
,_,
including_VBG [PRESP]
any_QUAN
resulting_VBG
from_PIN
from_PIN
contractual_JJ
or_CC
other_JJ
legal_JJ
rights_NN
or_CC
if_COND
it_PIT
is_VPRT [BEMA]
separable_PRED
,_,
that_DEMP
is_VPRT
,_,
research_NN
and_PHC
development_NOMZ
._.
Goodwill_NN
and_CC
identifiable_JJ
intangible_JJ
it_PIT
is_VPRT [BEMA]
capable_PRED
of_PIN
being_VBG [PASS]
separated_VBN
or_CC
divided_VBN
from_PIN
the_DT
acquired_VBN
entity_NOMZ
fixed_VBN
assets_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
as_IN
assets_NN
._.
Prior_RB
to_PIN
2002_CD
,_,
goodwill_NN
was_VBD
and_PHC
sold_VBD
,_,
transferred_VBN
,_,
licensed_VBN
,_,
rented_VBN
,_,
or_CC
exchanged_VBD
._.
In_CONJ
addition_NULL
,_,
amortised_VBN
over_IN
its_PIT
useful_JJ
life_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
goodwill_NN
arising_VBG [WZPRES]
US_FPP1
GAAP_NN
requires_VPRT [SUAV] [THATD]
amounts_NN
allocated_VBN
to_TO
acquired_VBN
in-process_NN
on_PIN
acquisitions_NOMZ
made_VBN
after_IN
30_CD
June_NN
2001_CD
._.
Effective_JJ
1_CD
January_NN
2002_CD
research_NN
and_PHC
development_NOMZ
that_TSUB
do_VPRT
not_XX0
have_VB
an_DT
alternative_JJ
use_NN
goodwill_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
amortised_VBN
under_IN
US_FPP1
GAAP_NN
,_,
but_CC
instead_CONJ
subject_JJ
to_TO
be_VB [PASS]
expensed_VBN
through_PIN
earnings_GER
in_PIN
the_DT
period_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
results_NN
in_PIN
a_DT
reversal_NN
of_PIN
goodwill_NN
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
investment_NOMZ
in_PIN
Waratah_NN
Pharmaceuticals_NN
Inc_NN
amortisation_NOMZ
charged_VBN
under_IN
UK_NN
GAAP_NN
._.
``_``
Intangible_JJ
fixed_JJ
assets_NN
''_''
``_``
Waratah_NN
''_''
''_''
was_VBD [BEMA]
fair_PRED
valued_VBN
based_VBN
on_PIN
prices_NN
quoted_VBN [WZPAST]
by_PIN
the_DT
recognized_VBN [PRIV]
under_IN
US_FPP1
GAAP_NN
purchase_NN
accounting_GER
requirements_NOMZ
Canadian_JJ
Venture_NN
Stock_NN
Exchange_NN
as_IN
of_PIN
each_QUAN
acquisition_NOMZ
date_NN
._.
''_''
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV] [THATD]
revenue_NN
earning_VBG [WZPRES]
life_NN
._.
Negative_JJ
The_DT
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
and_CC
the_DT
equity_NOMZ
value_NN
of_PIN
goodwill_NN
,_,
if_COND
any_QUAN
,_,
is_VPRT [BYPA]
eliminated_VBN
by_PIN
reducing_VBG
the_DT
value_NN
of_PIN
all_QUAN
nonthe_JJ
investment_NOMZ
was_VBD [PASS]
allocated_VBN
to_PIN
goodwill_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
current_JJ
assets_NN
acquired_VBN
._.
the_DT
investment_NOMZ
was_VBD [BEMA]
fair_PRED
valued_VBN
when_RB
the_DT
Company_NN
gained_VBD
control_NN
in_PIN
December_NN
2001_CD
._.
The_DT
deferred_VBN
taxation_NOMZ
impact_NN
of_PIN
all_QUAN
these_DEMO
b_NN
Tangible_JJ
fixed_JJ
assets_NN
Prior_RB
to_PIN
the_DT
introduction_NOMZ
of_PIN
FRS10_CD
differences_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
purchase_NN
price_NN
allocation_NOMZ
under_IN
UK_NN
GAAP_NN
for_PIN
business_NOMZ
acquisitions_NOMZ
,_,
where_RB
the_DT
aggregate_NN
of_PIN
for_PIN
US_FPP1
GAAP_NN
purposes_NN
._.
the_DT
fair_JJ
values_NN
of_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
exceeded_VBD
the_DT
cost_NN
of_PIN
the_DT
acquired_VBN
net_JJ
assets_NN
resulting_VBG [WZPRES]
in_PIN
negative_JJ
goodwill_NN
,_,
such_JJ
excess_JJ
In_PIN
January_NN
2002_CD
Waratah_NN
merged_VBD
with_PIN
Transition_NOMZ
Therapeutics_NN
Inc._NN
was_VBD [PASS]
credited_VBN
directly_RB
to_PIN
reserves_NN
._.
``_``
Under_IN
US_FPP1
GAAP_NN
such_JJ
excess_NN
is_VPRT
''_''
``_``
Transition_NOMZ
''_''
''_''
and_ANDC
Waratah_NN
shareholders_NN
were_VBD [PASS]
awarded_VBN
0.83333_CD
eliminated_VBN
by_PIN
proportionately_RB
reducing_VBG
the_DT
value_NN
of_PIN
the_DT
non-current_JJ
Transition_NOMZ
shares_NN
for_PIN
every_QUAN
one_CD
share_NN
of_PIN
Waratah_NN
held_VBD [PRIV]
._.
''_''
GAAP_NN
,_,
the_DT
Group_NN
continued_VBD
to_TO
account_VB
for_PIN
the_DT
investment_NOMZ
at_PIN
cost_NN
less_JJ
provision_NN
for_PIN
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
._.
S_NN
GAAP_NN
,_,
c_NN
Acquisition_NOMZ
of_PIN
RTP_NN
In_PIN
2001_CD
,_,
the_DT
Group_NN
purchased_VBD
the_DT
majority_NOMZ
on_PIN
the_DT
merger_NN
date_NN
the_DT
Group_NN
ceased_VBD
to_TO
apply_VB
the_DT
equity_NOMZ
method_NN
of_PIN
interest_NN
of_PIN
RTP_NN
through_PIN
a_DT
two-step_JJ
acquisition_NOMZ
effected_VBD
in_PIN
July_NN
and_PHC
accounting_GER
and_CC
carries_VPRT
the_DT
investment_NOMZ
in_PIN
Transition_NOMZ
at_PIN
adjusted_JJ
December_NN
2001_CD
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
aggregate_JJ
purchase_NN
price_NN
was_VBD [PASS]
cost_VBN
less_JJ
provision_NN
for_PIN
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
._.
39.4_CD
million_CD
,_,
including_VBG [PRESP]
35.3_CD
million_CD
of_PIN
ordinary_JJ
shares_NN
,_,
3.5_CD
million_CD
of_PIN
cash_NN
,_,
and_ANDC
0.6_CD
million_CD
in_PIN
acquisition_NOMZ
costs_NN
._.
The_DT
acquisition_NOMZ
was_VBD
d_SYM
Goodwill_NN
Under_IN
UK_NN
GAAP_NN
goodwill_NN
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
recorded_VBN
using_VBG
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
under_IN
both_DT
20_CD
years_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
is_VPRT
not_XX0
UK_NN
and_PHC
US_FPP1
GAAP_NN
._.
Goodwill_NN
was_VBD [PASS]
determined_VBN [SUAV] [PRIV]
as_IN
the_DT
difference_NN
amortised_VBN
but_CC
is_VPRT [BEMA]
subject_PRED
to_PIN
regular_JJ
impairment_NOMZ
tests_NN
._.
In_CONJ
addition_NULL
,_,
between_PIN
the_DT
purchase_NN
price_NN
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
assets_NN
under_IN
US_FPP1
GAAP_NN
,_,
the_DT
excess_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
assets_NN
acquired_VBD
acquired_VBN
._.
Under_IN
both_DT
UK_NN
and_PHC
US_FPP1
GAAP_NN
the_DT
investment_NOMZ
in_PIN
RTP_NN
was_VBD [BEMA]
in_PIN
December_NN
2001_CD
over_IN
the_DT
purchase_NN
consideration_NOMZ
negative_JJ
equity_NOMZ
accounted_VBD
for_PIN
until_IN
control_NN
was_VBD [PASS]
gained_VBN
on_PIN
27_CD
December_NN
2001_CD
goodwill_NN
resulting_VBG [WZPRES]
from_PIN
difference_NN
in_PIN
the_DT
purchase_NN
price_NN
allocation_NOMZ
and_CC
consolidated_JJ
from_PIN
that_DEMO
date_NN
on_PIN [STPR]
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
as_IN
a_DT
pro_PIN
rata_JJ
reduction_NOMZ
of_PIN
the_DT
non-current_JJ
3_CD
Shares_NN
issued_VBN
related_VBN
to_PIN
contingent_JJ
consideration_NOMZ
In_PIN
April_NN
2002_CD
,_,
assets_NN
acquired_VBD
including_VBG
in-process_JJ
research_NN
and_PHC
development_NOMZ
._.
all_QUAN
contingencies_NN
related_VBN [WZPAST]
to_PIN
the_DT
Deferred_NN
A_NN
Shares_NN
were_VBD [PASS]
removed_VBN
based_VBN
on_PIN
the_DT
first_JJ
commercial_JJ
launch_NN
of_PIN
Paxil_NN
CR_NN
._.
e_LS
In-process_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
In_PIN
2002_CD
,_,
the_DT
Group_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
removal_NN
of_PIN
these_DEMO
contingencies_NN
,_,
in_PIN
2002_CD
acquired_VBD
the_DT
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
._.
A_DT
charge_NN
of_PIN
the_DT
Group_NN
issued_VBD
12_CD
million_CD
Ordinary_NN
Shares_NN
to_PIN
Dr._NN
Gonella_NN
,_,
4.6_CD
million_CD
was_VBD [PASS]
expensed_VBN
in_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
the_DT
vendor_NN
of_PIN
Jago_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
shares_NN
were_VBD [PASS]
recorded_VBN
whereas_OSUB
under_IN
UK_NN
GAAP_NN
this_DEMP
was_VBD [PASS]
treated_VBN
as_IN
goodwill_NN
._.
In_PIN
2001_CD
,_,
the_DT
within_PIN
shareholders_NN
funds_NN
at_PIN
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
the_DT
Group_NN
purchased_VBD
the_DT
majority_NOMZ
interest_NN
of_PIN
RTP_NN
through_PIN
a_DT
two-step_JJ
contingencies_NN
were_VBD [PASS]
removed_VBN
._.
acquisition_NOMZ
effected_VBD
in_PIN
July_NN
and_PHC
December_NN
2001_CD
._.
The_DT
acquisitions_NOMZ
were_VBD [PASS]
recorded_VBN
using_VBG
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
under_IN
Under_IN
UK_NN
GAAP_NN
the_DT
shares_NN
were_VBD [PASS]
recorded_VBN
at_PIN
the_DT
market_NN
price_NN
both_DT
UK_NN
and_PHC
US_FPP1
GAAP_NN
._.
at_PIN
the_DT
date_NN
of_PIN
issuance_NN
of_PIN
deferred_JJ
shares_NN
20_CD
July_NN
2000_CD
._.
The_DT
adjustment_NOMZ
reverses_VPRT
the_DT
value_NN
of_PIN
equity_NOMZ
share_NN
capital_NN
and_CC
The_DT
adjustments_NOMZ
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
in_PIN
respect_NN
of_PIN
the_DT
premium_NN
in_PIN
the_DT
amount_NN
of_PIN
11.3_CD
million_CD
._.
A_DT
corresponding_JJ
RTP_NN
acquisition_NOMZ
relate_VPRT
mainly_RB
to_PIN
differences_NN
in_PIN
the_DT
valuation_NOMZ
of_PIN
adjustment_NOMZ
in_PIN
the_DT
amount_NN
of_PIN
9.4_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
within_PIN
purchase_NN
price_NN
consideration_NOMZ
,_,
the_DT
methods_NN
of_PIN
purchase_NN
price_NN
Goodwill_NN
and_CC
other_JJ
intangible_JJ
fixed_JJ
assets_NN
that_TSUB
represents_VPRT
the_DT
fair_JJ
allocation_NOMZ
and_CC
the_DT
amortisation_NOMZ
of_PIN
goodwill_NN
._.
In_PIN
2001_CD
,_,
this_DEMP
resulted_VBD
value_NN
of_PIN
shares_NN
issued_VBN
under_IN
US_FPP1
GAAP_NN
._.
in_PIN
a_DT
5.3_CD
million_CD
increase_NN
in_PIN
purchase_NN
consideration_NOMZ
and_PHC
differences_NN
in_PIN
the_DT
amounts_NN
assigned_VBN [WZPAST]
to_PIN
certain_JJ
tangible_JJ
and_CC
4_CD
Share-based_JJ
compensation_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Company_NN
does_VPRT
intangible_JJ
fixed_VBN
assets_NN
,_,
investments_NOMZ
and_CC
related_VBN
deferred_JJ
taxes_NN
._.
not_XX0
recognize_VB [PRIV]
compensation_NOMZ
expense_NN
associated_VBN [WZPAST]
with_PIN
its_PIT
stock_NN
Under_IN
US_FPP1
GAAP_NN
amounts_VPRT
allocated_VBN
to_TO
acquired_VBN
in-process_NN
option_NOMZ
plans_VPRT
granted_VBN [SUAV]
to_PIN
employees_NN
as_IN
the_DT
exercise_NN
price_NN
of_PIN
the_DT
research_NN
and_PHC
development_NOMZ
that_TSUB
do_VPRT
not_XX0
have_VB
an_DT
alternative_JJ
use_NN
options_NOMZ
equal_VPRT
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
have_VPRT [PEAS]
been_VBN [PASS]
expensed_VBN
through_PIN
earnings_GER
in_PIN
the_DT
period_NN
of_PIN
acquisition_NOMZ
:_:
under_IN
UK_NN
GAAP_NN
,_,
certain_JJ
of_PIN
these_DEMO
amounts_NN
are_VPRT
not_XX0
separately_RB
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
Accounting_GER
Principles_NN
Board_NN
identified_VBD
but_CC
considered_VBD [PRIV]
part_NN
of_PIN
goodwill_NN
._.
In_CONJ
addition_NULL
,_,
under_IN
UK_NN
Opinion_NN
APB_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
Issued_NN
to_PIN
Employees_NN
,_,
GAAP_NN
goodwill_NN
is_VPRT
being_VBG [PASS]
amortised_VBN
over_IN
20_CD
years_NN
on_PIN
a_DT
straight-line_JJ
and_PHC
related_JJ
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
plans_NN
._.
Accordingly_RB
,_,
basis_NN
while_OSUB
under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
resulting_VBG [WZPRES]
from_PIN
this_DEMO
compensation_NOMZ
expense_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
performance-based_JJ
acquisition_NOMZ
was_VBD [PASS]
not_XX0
amortised_VBN
._.
compensation_NOMZ
plans_NN
variable_JJ
plans_NN
where_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
performance_NN
criteria_NN
will_PRMD
be_VB [PASS]
met_VBN
and_CC
the_DT
options_NOMZ
exercised_VBN [WZPAST]
prior_RB
f_SYM
Contingent_JJ
consideration_NOMZ
charged_VBN [WZPAST]
to_PIN
goodwill_NN
The_DT
Group_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
options_NOMZ
issued_VBN
under_IN
these_DEMO
plans_NN
._.
No_DT
effected_VBD
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
and_PHC
Krypton_NN
through_PIN
the_DT
exchange_NN
compensation_NOMZ
expense_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
those_DEMO
plans_NN
that_THVC
of_PIN
warrants_NN
and_PHC
shares_NN
._.
The_DT
issuance_NN
of_PIN
certain_JJ
of_PIN
these_DEMO
warrants_NN
are_VPRT [PASS]
considered_VBN [PRIV]
fixed_VBN
option_NOMZ
plans_NN
under_IN
APB_NN
25_CD
and_ANDC
where_RB
the_DT
and_CC
shares_NN
is_VPRT [BEMA]
contingent_PRED
upon_PIN
the_DT
occurrence_NN
of_PIN
certain_JJ
future_JJ
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
plans_NN
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
that_TSUB
equals_VPRT
events_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
estimated_VBD [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
the_DT
contingent_JJ
consideration_NOMZ
to_TO
determine_VB [SUAV] [PRIV]
the_DT
acquisition_NOMZ
cost_NN
._.
The_DT
resulting_VBG
goodwill_NN
was_VBD [PASS]
eliminated_VBN
against_PIN
shareholders_NN
funds_NN
._.
5_CD
Revenue_NN
recognition_NOMZ
Under_IN
UK_NN
GAAP_NN
contract_NN
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
it_PIT
is_VPRT [PASS]
earned_VBN
and_CC
non-refundable_JJ
and_CC
to_PIN
the_DT
extent_NN
Under_IN
US_FPP1
GAAP_NN
the_DT
acquisition_NOMZ
cost_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
to_TO
remove_VB
that_DEMO
there_EX
are_VPRT
no_SYNE
future_JJ
obligations_NOMZ
pursuant_JJ
to_PIN
the_DT
revenue_NN
,_,
in_PIN
the_DT
contingent_JJ
consideration_NOMZ
,_,
which_WDT [SERE]
is_VPRT [SPAU] [PASS]
only_DWNT
recognized_VBN [PRIV]
when_RB [WHCL]
it_PIT
accordance_NN
with_PIN
the_DT
contract_NN
terms_NN
._.
Refundable_JJ
contract_NN
revenue_NN
is_VPRT [BEMA]
determinable_PRED
beyond_IN
reasonable_JJ
doubt_NN
,_,
therefore_CONJ
contingent_JJ
is_VPRT [PASS]
treated_VBN
as_IN
deferred_VBN
until_IN
such_EMPH
a_NULL
time_NN
as_IN
it_PIT
is_VPRT
no_RB
longer_RB
consideration_NOMZ
charged_VBN [WZPAST]
to_PIN
goodwill_NN
reserves_NN
has_VPRT [PEAS]
been_VBN [PASS]
reversed_VBN
refundable_JJ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
SAB_NN
101_CD
requires_VPRT [SUAV]
deferral_JJ
and_CC
out_PIN
of_PIN
shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
._.
amortisation_NOMZ
of_PIN
up-front_JJ
licensing_GER
fees_NN
where_RB
there_EX
is_VPRT
a_DT
continuing_VBG
involvement_NOMZ
with_PIN
the_DT
licensed_JJ
asset_NN
through_PIN
the_DT
provision_NN
of_PIN
2_CD
Deferred_JJ
shares_NN
and_PHC
shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
Under_IN
research_NN
and_PHC
development_NOMZ
services_NN
,_,
manufacturing_VBG
services_NN
or_CC
UK_NN
GAAP_NN
,_,
contingent_JJ
consideration_NOMZ
payable_JJ
in_PIN
connection_NOMZ
with_PIN
other_JJ
similar_JJ
activities_NOMZ
even_RB
if_COND
the_DT
fee_NN
is_VPRT [BEMA]
non-refundable_PRED
._.
As_IN
a_DT
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
is_VPRT [PASS]
included_VBN
within_PIN
shareholders_NN
funds_NN
as_IN
result_NN
,_,
under_IN
US_FPP1
GAAP_NN
certain_JJ
non-refundable_JJ
up-front_JJ
payments_NOMZ
deferred_VBN
shares_NN
._.
have_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
over_IN
the_DT
development_NOMZ
period_NN
of_PIN
the_DT
contract_NN
term_NN
on_PIN
certain_JJ
agreements_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
contingent_JJ
consideration_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
only_DWNT
when_RB
determinable_JJ
beyond_IN
reasonable_JJ
doubt_NN
,_,
therefore_CONJ
deferred_VBN
shares_NN
Deferred_JJ
revenue_NN
reflects_VPRT [PRIV]
the_DT
amount_NN
of_PIN
revenue_NN
not_XX0
currently_RB
and_CC
shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
have_VPRT [PEAS]
been_VBN [PASS]
reversed_VBN
out_PIN
of_PIN
eligible_NN
for_PIN
recognition_NOMZ
under_IN
US_FPP1
GAAP_NN
as_RB
well_RB
as_IN
the_DT
reversal_NN
shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
._.
of_PIN
8.8_CD
million_CD
31_CD
December_NN
2002_CD
:_:
7.8_CD
million_CD
deferred_JJ
income_NN
under_IN
UK_NN
GAAP_NN
related_VBN [WZPAST]
to_PIN
the_DT
sale_NN
of_PIN
royalty_NN
interests_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
treated_VBN
as_IN
debt_NN
under_IN
US_FPP1
GAAP_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
88_CD
89_CD
reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
principles_NN
continued_VBD
6_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
Under_IN
UK_NN
GAAP_NN
payments_NOMZ
received_VBD
from_PIN
is_VPRT [BEMA]
not_XX0
available_PRED
for_PIN
the_DT
delivered_VBN
items_NN
then_RB
the_DT
residual_JJ
method_NN
a_DT
third_JJ
party_NN
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
proportion_NOMZ
of_PIN
potential_JJ
future_NN
must_NEMD
be_VB [PASS]
used_VBN
._.
This_DEMO
method_NN
requires_VPRT [SUAV]
that_THVC
the_DT
amount_NN
allocated_VBN
royalty_NN
streams_NN
from_PIN
a_DT
selection_NOMZ
of_PIN
products_NN
,_,
and_ANDC
used_VBD
to_TO
fund_VB
the_DT
to_PIN
the_DT
undelivered_JJ
items_NN
in_PIN
the_DT
arrangement_NOMZ
is_VPRT [BEMA]
their_TPP3
full_JJ
fair_JJ
value_NN
._.
internal_JJ
research_NN
and_PHC
development_NOMZ
of_PIN
products_NN
,_,
are_VPRT [PASS]
reflected_VBN [PRIV]
within_PIN
This_DEMP
would_PRMD
result_VB
in_PIN
the_DT
discount_NN
,_,
if_COND
any_QUAN
,_,
being_VBG [PASS]
allocated_VBN
to_PIN
the_DT
other_JJ
operating_GER
income_NN
when_RB
the_DT
risk_NN
of_PIN
reimbursement_NOMZ
has_VPRT [PEAS]
delivered_VBN
items_NN
._.
This_DEMO
consensus_NN
is_VPRT [BEMA]
effective_JJ
prospectively_RB
for_PIN
effectively_RB
been_VBN [PASS]
transferred_VBN
to_PIN
the_DT
third_JJ
party_NN
._.
Royalties_NN
paid_VBD
arrangements_NOMZ
entered_VBD
into_PIN
in_PIN
fiscal_JJ
periods_NN
beginning_VBG [WZPRES]
after_IN
to_PIN
third_JJ
parties_NN
are_VPRT [PASS]
treated_VBN
as_IN
cost_NN
of_PIN
goods_NN
sold_VBN
._.
15_CD
June_NN
2003_CD
,_,
which_WDT [SERE]
,_,
for_PIN
the_DT
Group_NN
,_,
is_VPRT [BEMA]
1_CD
January_NN
2004_CD
._.
The_DT
Group_NN
is_VPRT
assessing_VBG
the_DT
impact_NN
of_PIN
this_DEMO
interpretation_NOMZ
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
such_JJ
payments_NOMZ
to_TO
be_VB [PASS]
recorded_VBN
as_IN
debt_NN
where_RB
there_EX
is_VPRT
continuing_VBG
involvement_NOMZ
in_PIN
the_DT
generation_NOMZ
of_PIN
the_DT
cash_NN
flows_VPRT
In_PIN
January_NN
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
Interpretation_NOMZ
No._NN
._.
The_DT
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
the_DT
statement_NOMZ
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
FIN_NN
46_CD
and_CC
in_PIN
of_PIN
operations_NOMZ
includes_VPRT
the_DT
reversal_NN
of_PIN
other_JJ
operating_GER
income_NN
December_NN
2003_CD
issued_VBD
FIN46_CD
R_NN
,_,
a_DT
revision_NN
of_PIN
this_DEMO
interpretation_NOMZ
._.
recorded_VBN [PASTP]
from_PIN
the_DT
third_JJ
party_NN
as_RB
well_RB
as_IN
recording_VBG
the_DT
interest_NN
Under_IN
this_DEMO
interpretation_NOMZ
,_,
certain_JJ
entities_NOMZ
known_VBN [PRIV]
as_IN
Variable_JJ
charge_NN
for_PIN
the_DT
period_NN
on_PIN
the_DT
outstanding_JJ
debt_NN
balance_NN
._.
Repayments_NOMZ
Interest_NN
Entities_NOMZ
VIE_NN
must_NEMD
be_VB [BYPA]
consolidated_VBN
by_PIN
the_DT
primary_JJ
made_VBN
to_PIN
third_JJ
parties_NN
in_PIN
the_DT
form_NN
of_PIN
royalty_NN
payments_NOMZ
that_TSUB
are_VPRT
beneficiary_NN
of_PIN
the_DT
entity_NOMZ
._.
The_DT
primary_JJ
beneficiary_NN
is_VPRT [SPAU] [PASS]
generally_RB
expensed_VBN
under_IN
UK_NN
GAAP_NN
are_VPRT [PASS]
reversed_VBN
under_IN
US_FPP1
GAAP_NN
and_CC
are_VPRT [PASS]
defined_VBN
as_IN
having_VBG
the_DT
majority_NOMZ
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
arising_VBG [WZPRES]
treated_VBN
as_IN
repayment_NOMZ
of_PIN
debt_NN
._.
For_PIN
VIEs_NN
in_PIN
which_WDT [PIRE]
a_DT
significant_JJ
but_CC
not_XX0
majority_NOMZ
variable_JJ
interest_NN
is_VPRT [PASS]
held_VBN [PRIV]
,_,
certain_JJ
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
._.
The_DT
7_CD
Employee_NN
Benefit_NN
Trust_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Ordinary_NN
Shares_NN
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
assessing_VBG
the_DT
impact_NN
of_PIN
this_DEMO
interpretation_NOMZ
Company_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
as_IN
it_PIT
will_PRMD
be_VB [BEMA]
effective_PRED
for_PIN
the_DT
Group_NN
beginning_VBG [WZPRES]
1_CD
January_NN
2004_CD
._.
The_DT
Trust_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
and_CC
accounted_VBD
for_PIN
as_IN
investments_NOMZ
._.
effect_NN
of_PIN
this_DEMO
interpretation_NOMZ
could_POMD
be_VB
that_DEMO
minority_NOMZ
investments_NOMZ
The_DT
difference_NN
between_PIN
the_DT
purchase_NN
price_NN
of_PIN
the_DT
shares_NN
and_CC
the_DT
that_DEMO
the_DT
Group_NN
holds_VPRT [PRIV]
in_PIN
certain_JJ
companies_NN
and_ANDC
which_WDT
it_PIT
is_VPRT [BEMA]
also_RB
the_DT
exercise_NN
price_NN
of_PIN
the_DT
award_NN
is_VPRT [PASS]
charged_VBN
,_,
or_CC
credited_VBN
,_,
to_PIN
the_DT
profit_NN
major_JJ
provider_NN
of_PIN
development_NOMZ
services_NN
may_POMD
required_VBN [SUAV]
to_TO
be_VB
and_CC
loss_NN
account_NN
over_IN
the_DT
period_NN
of_PIN
service_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
consolidated_JJ
if_COND
,_,
within_PIN
the_DT
definitions_NOMZ
of_PIN
the_DT
interpretation_NOMZ
,_,
the_DT
award_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
._.
Group_NN
maintains_VPRT [PUBV]
the_DT
majority_NOMZ
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
this_DEMO
third-party_JJ
entity_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
Ordinary_NN
Shares_NN
of_PIN
the_DT
Company_NN
purchased_VBN [WZPAST]
by_PIN
the_DT
Employee_NN
Benefit_NN
Trust_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
at_PIN
cost_NN
as_IN
treasury_NN
In_PIN
May_POMD
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
FAS_NN
150_CD
,_,
Accounting_GER
For_PIN
Certain_NN
shares_NN
which_WDT [WHSUB]
reduce_VPRT
shareholders_NN
funds_NN
._.
Gains_NN
or_CC
losses_NN
arising_VBG [WZPRES]
Financial_JJ
Instruments_NOMZ
with_PIN
Characteristics_NN
of_PIN
both_DT
Liabilities_NOMZ
on_PIN
subsequent_JJ
issuance_NN
of_PIN
the_DT
shares_NN
to_PIN
employees_NN
are_VPRT [PASS]
recorded_VBN
and_CC
Equity_NOMZ
FAS_NN
150_CD
._.
This_DEMO
standard_JJ
establishes_VPRT [PRIV]
how_RB [WHCL]
an_DT
issuer_NN
as_IN
adjustments_NOMZ
to_PIN
shareholders_NN
funds_NN
._.
The_DT
reduction_NOMZ
in_PIN
cost_NN
,_,
which_WDT [SERE]
classifies_VPRT
and_PHC
measures_VPRT
certain_JJ
financial_JJ
instruments_NOMZ
with_PIN
is_VPRT [PASS]
expensed_VBN
under_IN
UK_NN
GAAP_NN
,_,
is_VPRT [PASS]
reversed_VBN
under_IN
US_FPP1
GAAP_NN
to_TO
maintain_VB [PUBV]
characteristics_NN
of_PIN
both_DT
liabilities_NOMZ
and_PHC
equity_NOMZ
and_CC
requires_VPRT [SUAV]
that_THVC
the_DT
treasury_NN
shares_NN
at_PIN
cost_NN
._.
All_QUAN
employee_NN
compensation_NOMZ
expense_NN
is_VPRT [BEMA]
an_DT
issuer_NN
classify_VB
a_DT
financial_JJ
instrument_NOMZ
that_DEMP
is_VPRT [BEMA]
within_PIN
its_PIT
scope_NN
recorded_VBN
under_IN
APB_NN
25_CD
._.
as_IN
a_DT
liability_NOMZ
or_CC
an_DT
asset_NN
in_PIN
some_QUAN
circumstances_NN
._.
FAS_NN
150_CD
will_PRMD
be_VB [BEMA]
effective_PRED
for_PIN
financial_JJ
instruments_NOMZ
entered_VBD
into_PIN
or_CC
modified_VBN
after_IN
8_CD
Financial_NN
instruments_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
periodic_JJ
gains_NN
and_PHC
losses_NN
31_CD
May_POMD
2003_CD
,_,
and_ANDC
otherwise_CONJ
is_VPRT [BEMA]
effective_PRED
for_PIN
the_DT
group_NN
for_PIN
periods_NN
on_PIN
interest_NN
and_CC
foreign_JJ
currency_NN
derivatives_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
beginning_GER
after_IN
10_CD
June_NN
2003_CD
._.
The_DT
Group_NN
believes_VPRT [PRIV]
that_THVC
the_DT
adoption_NOMZ
until_IN
the_DT
operational_JJ
transactions_NOMZ
to_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
linked_VBN
occur_VPRT
._.
of_PIN
this_DEMO
standard_NN
will_PRMD
not_XX0
have_VB
a_DT
material_NN
effect_NN
on_PIN
the_DT
groups_NN
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
records_NN
all_QUAN
derivative_JJ
instruments_NOMZ
on_PIN
results_NN
of_PIN
operation_NOMZ
or_CC
financial_JJ
position_NOMZ
._.
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
with_PIN
changes_NN
in_PIN
fair_JJ
values_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
earnings_GER
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
reviewed_VBN
its_PIT
contractual_JJ
arrangements_NOMZ
for_PIN
the_DT
existence_NN
of_PIN
embedded_VBN
derivatives_NN
that_TSUB
should_NEMD
be_VB [SPAU] [PASS]
separately_RB
accounted_VBN
for_PIN
under_IN
SFAS_NN
133_CD
._.
If_COND
embedded_VBN
derivatives_NN
are_VPRT [PASS]
identified_VBN
,_,
they_TPP3
are_VPRT [PASS]
recorded_VBN
separately_RB
from_PIN
their_TPP3
host_NN
contracts_NN
at_PIN
fair_JJ
value_NN
,_,
with_PIN
changes_NN
in_PIN
fair_JJ
value_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
current_JJ
earnings_GER
._.
``_``
Recent_JJ
US_FPP1
GAAP_NN
Pronouncements_NOMZ
In_PIN
November_NN
2002_CD
,_,
the_DT
Emerging_VBG
Issues_NN
Task_NN
Force_NN
EITF_NN
reached_VBD
a_DT
consensus_NN
on_PIN
EITF_NN
00-21_CD
,_,
''_''
``_``
Revenue_NN
Arrangements_NOMZ
with_PIN
Multiple_NN
Deliverables_NN
,_,
''_''
''_''
related_VBN [PASTP]
to_PIN
the_DT
timing_NN
of_PIN
revenue_NN
recognition_NOMZ
for_PIN
arrangements_NOMZ
in_PIN
which_WDT [PIRE]
goods_NN
or_CC
services_NN
or_CC
both_DT
are_VPRT [PASS]
delivered_VBN
separately_RB
in_PIN
a_DT
bundled_VBN
sales_NN
arrangement_NOMZ
._.
''_''
The_DT
EITF_NN
requires_VPRT [SUAV]
that_THVC
when_RB
the_DT
deliverables_NN
included_VBD
in_PIN
this_DEMO
type_NN
of_PIN
arrangement_NOMZ
meet_VPRT
certain_JJ
criteria_NN
they_TPP3
should_NEMD
be_VB [PASS]
accounted_VBN
for_PIN
separately_RB
as_IN
separate_JJ
units_NN
of_PIN
accounting_GER
._.
This_DEMP
may_POMD
result_VB
in_PIN
a_DT
difference_NN
in_PIN
the_DT
timing_NN
of_PIN
revenue_NN
recognition_NOMZ
,_,
but_CC
will_PRMD
not_XX0
result_VB
in_PIN
a_DT
change_NN
in_PIN
the_DT
total_JJ
amount_NN
of_PIN
revenue_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
a_DT
bundled_VBN
sales_NN
arrangement_NOMZ
._.
The_DT
allocation_NOMZ
of_PIN
revenue_NN
to_PIN
the_DT
separate_JJ
deliverables_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
relative_JJ
fair_JJ
value_NN
of_PIN
each_QUAN
item_NN
._.
If_COND
the_DT
fair_JJ
value_NN
SkyePharma_NN
annual_JJ
report_NN
2003_CD
company_NN
information_NOMZ
and_PHC
advisors_NN
Registered_NN
and_PHC
Head_NN
Office_NN
Bankers_NN
105_CD
Piccadilly_NN
,_,
National_NN
Westminster_NN
Bank_NN
plc_NN
London_NN
W1J_NN
7NJ_NN
Bishopsgate_NN
Business_NOMZ
Centre_NN
Telephone_NN
:_:
020 7491 1777_CD
PO_NN
Box_NN
34_CD
Fax_NN
:_:
020 7491 3338_CD
15_CD
Bishopsgate_NN
Registered_NN
No_NN
:_:
107582_CD
London_NN
EC2P_NN
2AP_NN
Secretary_NN
:_:
Douglas_NN
Parkhill_NN
Registrars_NN
Auditors_NN
Capita_NN
Registrars_NN
LLP_NN
The_DT
Registry_NN
Chartered_NN
Accountants_NN
34_CD
Beckenham_NN
Road_NN
1_CD
Embankment_NOMZ
Place_NN
Beckenham_NN
London_NN
WC2N_NN
6RH_NN
Kent_NN
BR3_NN
4TU_NN
Solicitors_NN
Depository_NN
UK_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Stringer_NN
Saul_NN
101_CD
Barclay_NN
Street_NN
17_CD
Hanover_NN
Square_NN
New_NN
York_NN
London_NN
W1S_NN
1HU_NN
NY_NN
10286_CD
USA_NN
US_FPP1
Sullivan_NN
&_CC
Cromwell_NN
One_CD
New_NN
Fetter_NN
Lane_NN
London_NN
EC4A_NN
1AN_NN
Corporate_NN
Broker_NN
and_CC
financial_JJ
adviser_NN
Credit_NN
Suisse_NN
First_NN
Boston_NN
20_CD
Columbus_NN
Courtyard_NN
London_NN
E14_NN
4DA_NN
skyepharma_NN
._.
